Published online before print August 25, 2008, doi: 10.1161/CIRCULATIONAHA.107.762047
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 2008;118:1138-1145.)
© 2008 American Heart Association, Inc.
Interventional Cardiology |
Delayed Arterial Healing and Increased Late Stent Thrombosis at Culprit Sites After Drug-Eluting Stent Placement for Acute Myocardial Infarction Patients
An Autopsy Study
From CVPath Institute, Inc, Gaithersburg, Md (G.N., M.J., E.L., R.K., A.P.B., F.D.K., R.V.); Emory University School of Medicine, Atlanta, Ga (A.V.F.); Miami Dade County Medical Examiner Department, Miami, Fla (E.K.M.); and Massachusetts General Hospital, Boston (H.K.G.).
Correspondence to Renu Virmani, MD, Medical Director, CVPath Institute, Inc, 19 Firstfield Rd, Gaithersburg, MD 20878. E-mail rvirmani{at}cvpath.org
Received December 19, 2007; accepted June 30, 2008.
Background— The long-term safety of drug-eluting stents (DES) for acute myocardial infarction (AMI) remains uncertain. Using autopsy data, we evaluated the pathological responses of the stented segment in patients treated with DES for AMI and compared with patients with stable angina.
Methods and Results— From the CVPath Registry of 138 DES autopsies, we identified 25 patients who presented with AMI and had an underlying necrotic core with a ruptured fibrous cap. Twenty-six patients who had stable angina with thick-cap fibroatheroma treated by DES were selected as controls. Histomorphometric analysis was performed in patients with >30-day stent duration. We compared the response to stenting at the culprit site in these 2 groups and to nonculprit sites within each stent. Late stent thrombosis was significantly less frequent in stable (11%) than in AMI (41%; P=0.04) patients. Although neointimal thickness in the AMI culprit site was significantly less (median, 0.04 mm; interquartile range [IQR], 0.02 to 0.09 mm), the prevalence of uncovered struts (49%; IQR, 16% to 96%), fibrin deposition (63±28%), and inflammation (35%; IQR, 27% to 49%) were significantly greater compared with the culprit site in stable patients (neointimal thickness: 0.11 mm [IQR, 0.07 to 0.21 mm], P=0.008; uncovered struts: 9% [IQR, 0% to 39%], P=0.01; fibrin: 36±27%, P=0.008; inflammation, 17% [IQR, 7% to 25%], P=0.003) and the nonculprit site within each stent.
Conclusions— Vessel healing at the culprit site in AMI patients treated with DES is substantially delayed compared with the culprit site in patients receiving DES for stable angina, emphasizing the importance of underlying plaque morphology in the arterial response to DES. Our data suggest an increased risk of thrombotic complications in patients treated with DES for AMI.
CLINICAL PERSPECTIVE
This article has been cited by other articles:
 |
|
 |
|
  A. Maehara, G. S. Mintz, A. J. Lansky, B. Witzenbichler, G. Guagliumi, B. Brodie, M. A. Kellett Jr, H. Parise, R. Mehran, and G. W. Stone Volumetric Intravascular Ultrasound Analysis of Paclitaxel-Eluting and Bare Metal Stents in Acute Myocardial Infarction: The Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction Intravascular Ultrasound Substudy Circulation, November 10, 2009; 120(19): 1875 - 1882. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. G. Bezerra, M. A. Costa, G. Guagliumi, A. M. Rollins, and D. I. Simon Intracoronary Optical Coherence Tomography: A Comprehensive Review: Clinical and Research Applications J. Am. Coll. Cardiol. Intv., November 1, 2009; 2(11): 1035 - 1046. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. V. Finn, G. Nakazawa, F. Kolodgie, and R. Virmani Drug eluting or bare metal stent for acute myocardial infarction: an issue of safety? Eur. Heart J., August 1, 2009; 30(15): 1828 - 1830. [Full Text] [PDF]
|
|
|
|
|
|
G. G. Camici, J. Steffel, I. Amanovic, A. Breitenstein, J. Baldinger, S. Keller, T. F. Luscher, and F. C. Tanner Rapamycin promotes arterial thrombosis in vivo: implications for everolimus and zotarolimus eluting stents Eur. Heart J., June 29, 2009; (2009) ehp259v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. R. Dixon, C. L. Grines, and W. W. O'Neill The year in interventional cardiology. J. Am. Coll. Cardiol., June 2, 2009; 53(22): 2080 - 2097. [Full Text] [PDF]
|
|
|
|
 |
|
 G. W. Stone, A. J. Lansky, S. J. Pocock, B. J. Gersh, G. Dangas, S. C. Wong, B. Witzenbichler, G. Guagliumi, J. Z. Peruga, B. R. Brodie, et al. Paclitaxel-Eluting Stents versus Bare-Metal Stents in Acute Myocardial Infarction N. Engl. J. Med., May 7, 2009; 360(19): 1946 - 1959. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. S. Brar, M. B. Leon, G. W. Stone, R. Mehran, J. W. Moses, S. K. Brar, and G. Dangas Use of drug-eluting stents in acute myocardial infarction: a systematic review and meta-analysis. J. Am. Coll. Cardiol., May 5, 2009; 53(18): 1677 - 1689. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Gonzalo, P. Barlis, P. W. Serruys, H. M. Garcia-Garcia, Y. Onuma, J. Ligthart, and E. Regar Incomplete Stent Apposition and Delayed Tissue Coverage Are More Frequent in Drug-Eluting Stents Implanted During Primary Percutaneous Coronary Intervention for ST-Segment Elevation Myocardial Infarction Than in Drug-Eluting Stents Implanted for Stable/Unstable Angina: Insights From Optical Coherence Tomography J. Am. Coll. Cardiol. Intv., May 1, 2009; 2(5): 445 - 452. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. E. Cutlip Drug-Eluting or Bare-Metal Stents for ST Elevation Myocardial Infarction Can Observational Data Balance the Risk Benefit Equation? Circ Cardiovasc Interv, December 1, 2008; 1(3): 161 - 163. [Full Text] [PDF]
|
|
|
|
|
|
M. E. Pfisterer Late Stent Thrombosis After Drug-Eluting Stent Implantation for Acute Myocardial Infarction: A New Red Flag Is Raised Circulation, September 9, 2008; 118(11): 1117 - 1119. [Full Text] [PDF]
|
|